MET and neoplasm: Despite the protein overexpression of MET, in the absence of additional genomic alterations in MET, tumor cells were ROS1-dependent, as evidenced by the initial durable responses to ROS1 inhibitors crizotinib (14 months) and then lorlatinib (30 months).